Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.480 -0.090 (-2.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Preview: Atea Pharmaceuticals ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Preview: Atea Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir ↗
 
Via Benzinga
News headline image
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recap: Atea Pharmaceuticals Q2 Earnings ↗
  Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Short Volatility Alert: Atea Pharmaceuticals ↗
On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The... 
Via Benzinga
News headline image
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 35 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Earnings Preview ↗
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
News headline image
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
News headline image
Stocks Selling For Less Than Cash Per Share ↗
How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.